MillerJEAhnSHMarksRMMonsantoSPFazleabasATKotiMet al
Semaglutide has a half-life of approximately one week, meaning its effects wane over several weeks, with most of the drug cleared by about 4-5 weeks
The current evidence base primarily from animal studies and limited human trials suggests the following potential applications: Improved sleep quality increased proportion of slow-wave sleep, reduced sleep latency, fewer nocturnal cortisol spikes Cortisol normalisation reduced HPA hyperactivation, particularly relevant in high-stress or metabolically burdened patients Nociceptive effects several studies indicate DSIP modulates pain processing, with implications for patients whose poor sleep is pain-driven (3) Antioxidant activity may reduce oxidative stress markers, which are elevated in both sleep-deprived and insulin-resistant individuals Neuroendocrine support preliminary evidence of effects on LH, FSH, and somatostatin hormones that regulate testosterone, oestrogen, and growth hormone release Potential stress adaptation some data suggest DSIP may reduce the physiological stress response magnitude without blunting alertness It is important to be precise here
VAT and ASAT decreased by up to 43.5 percent after 48 weeks
The free fatty acid side chain was coupled to the peptide to facilitate binding to albumin in plasma and interstitial fluid
It is also important to work with a healthcare provider who provides continued monitoring and support
